Category - Developments

Developments

Dimerix posts positive Phase 2a in CKD

Dimerix (ASX:DXB) announced positive safety and efficacy data following a 27-patient Phase 2a proof-of-concept, dose escalation study in chronic kidney disease (CKD) for lead program, DMX-200. Dimerix will now progress...

July 12, 2017

Developments

Titan’s Probuphine gains more media attention

The Herald Bulletin of Madison County, Indiana has published a feature about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for the treatment of opioid addiction. The article highlights Probuphine’s...

July 10, 2017

Developments

Titan Pharma, Walter Reed collaborating in antimalarial implants

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a cooperative research and development agreement with Walter Reed Army Institute of Research and Southwest Research Institute to evaluate development of ProNeura...

July 6, 2017

Developments

Scientus inks cannabis supply pact with Aphria

Closely-held Scientus Pharma, through its HydRx Farms unit, has entered into a major wholesale purchase agreement with Aphria (TSX:APH; OTCQB:APHQF). Under the accord, Aphria would supply more than 25,000 fully-grown...

July 4, 2017

Developments

FDA grants priority review to Theratechnologies’ ibalizumab

Theratechnologies (TSX:TH) has been notified by its partner, TaiMed Biologics, that the FDA has accepted for review the biologics license application for ibalizumab as a treatment for multidrug-resistant human...

June 30, 2017

Developments

Profound Medical to expand collaboration with Royal Philips’, acquire Sonalleve unit

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has agreed to expand an existing collaboration with Royal Philips (NYSE:PHG; AEX:PHIA) and acquire Philips’ Sonalleve MR-HIFU business, establishing Profound as a market leader...

June 30, 2017

Developments

Fortune hails Titan’s ProNeura technology

Fortune.com has featured Titan Pharmaceuticals (NASDAQ:TTNP) and its ProNeura technology, calling it a “formidable new class of pharmaceutical implants.” The article said Titan’s Probuphine implant for the treatment of...

June 28, 2017

Developments

Stryker to acquire Novadaq Technologies

Stryker (NYSE:SYK) has agreed to acquire Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) for $11.75 a share, implying a total equity value of approximately $701-million. The transaction price represents a premium of...

June 19, 2017

Developments

Knight NDS for Probuphine in Canada accepted for review

Knight Therapeutics’ (TSX:GUD) New Drug Submission (NDS) for Probuphine, a subdermal implant of buprenorphine for the treatment of opioid drug dependence, has been accepted for review by Health Canada. Knight and...

June 13, 2017

Developments

3DS advances Hodgkin’s lymphoma test

The clinical trial component of 3D Signatures’ (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) Hodgkin’s lymphoma test (Telo-HL) validation program is under way. This process is referred to as Stage 3 of the validation program...

June 8, 2017

Category - Developments

Subscribe